SI2694037T1 - Formulacije, ki obsegajo 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol - Google Patents

Formulacije, ki obsegajo 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol

Info

Publication number
SI2694037T1
SI2694037T1 SI201230821A SI201230821A SI2694037T1 SI 2694037 T1 SI2694037 T1 SI 2694037T1 SI 201230821 A SI201230821 A SI 201230821A SI 201230821 A SI201230821 A SI 201230821A SI 2694037 T1 SI2694037 T1 SI 2694037T1
Authority
SI
Slovenia
Prior art keywords
octylphenyl
diol
propane
formulations
ethyl
Prior art date
Application number
SI201230821A
Other languages
English (en)
Inventor
Supriya Rane
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45953284&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2694037(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2694037T1 publication Critical patent/SI2694037T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
SI201230821A 2011-04-01 2012-03-30 Formulacije, ki obsegajo 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol SI2694037T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161470747P 2011-04-01 2011-04-01
US201161545835P 2011-10-11 2011-10-11
EP12714163.8A EP2694037B1 (en) 2011-04-01 2012-03-30 Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
PCT/US2012/031340 WO2012135561A1 (en) 2011-04-01 2012-03-30 Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol

Publications (1)

Publication Number Publication Date
SI2694037T1 true SI2694037T1 (sl) 2017-01-31

Family

ID=45953284

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201231732T SI3143990T1 (sl) 2011-04-01 2012-03-30 Formulacije, ki vsebujejo 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol
SI201230821A SI2694037T1 (sl) 2011-04-01 2012-03-30 Formulacije, ki obsegajo 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201231732T SI3143990T1 (sl) 2011-04-01 2012-03-30 Formulacije, ki vsebujejo 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol

Country Status (35)

Country Link
US (5) US9592208B2 (sl)
EP (2) EP2694037B1 (sl)
JP (1) JP6019101B2 (sl)
KR (1) KR102027014B1 (sl)
CN (1) CN103476400B (sl)
AR (1) AR085749A1 (sl)
AU (1) AU2012236357B2 (sl)
BR (1) BR112013024430B1 (sl)
CA (1) CA2831600C (sl)
CL (1) CL2013002810A1 (sl)
CO (1) CO6771459A2 (sl)
CY (2) CY1118423T1 (sl)
DK (2) DK2694037T3 (sl)
EA (2) EA027721B1 (sl)
EC (1) ECSP13012912A (sl)
ES (2) ES2610966T3 (sl)
GT (1) GT201300227A (sl)
HK (1) HK1190309A1 (sl)
HR (2) HRP20170021T1 (sl)
HU (1) HUE031286T2 (sl)
IL (1) IL228250B (sl)
JO (1) JO3177B1 (sl)
LT (2) LT2694037T (sl)
MA (1) MA34981B1 (sl)
MX (1) MX342522B (sl)
MY (2) MY175633A (sl)
PE (2) PE20140162A1 (sl)
PL (2) PL2694037T3 (sl)
PT (2) PT2694037T (sl)
RS (1) RS59917B1 (sl)
SG (1) SG193256A1 (sl)
SI (2) SI3143990T1 (sl)
TW (1) TWI528958B (sl)
WO (1) WO2012135561A1 (sl)
ZA (1) ZA201306636B (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
CN103222966A (zh) * 2013-04-01 2013-07-31 北京万全德众医药生物技术有限公司 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
JP2018502168A (ja) * 2015-01-20 2018-01-25 ハンダ ファーマシューティカルズ エルエルシー 安定な固体フィンゴリモド剤形
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ES2230571T3 (es) 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
IL131608A (en) 1997-02-27 2003-02-12 Welfide Corp Pharmaceutical composition and kit containing the same
ATE298740T1 (de) 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森  昭 ウイルス性心筋炎の予防または治療薬剤
JP2004507552A (ja) 2000-08-31 2004-03-11 メルク エンド カムパニー インコーポレーテッド 免疫調節剤としてのリン酸誘導体
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
KR101367574B1 (ko) * 2003-04-08 2014-02-25 미쓰비시 타나베 파마 코퍼레이션 S1p 수용체 아고니스트 및 당 알콜을 포함하는 고형 제약 조성물
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
US7888527B2 (en) 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
ES2748432T3 (es) * 2006-09-26 2020-03-16 Novartis Ag Composiciones farmacéuticas que comprenden un modulador de S1P
CL2007003784A1 (es) 2006-12-21 2008-06-27 Abbott Lab Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato
TW200927142A (en) * 2007-10-12 2009-07-01 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
US20100160259A1 (en) 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist

Also Published As

Publication number Publication date
LT2694037T (lt) 2017-01-10
MY175633A (en) 2020-07-02
EA201391442A1 (ru) 2014-04-30
EA201790436A3 (ru) 2018-03-30
MA34981B1 (fr) 2014-03-01
EA035686B1 (ru) 2020-07-27
PL3143990T3 (pl) 2020-05-18
LT3143990T (lt) 2020-02-25
CN103476400B (zh) 2016-11-09
MX342522B (es) 2016-10-03
PT2694037T (pt) 2017-01-17
US20190247335A1 (en) 2019-08-15
DK2694037T3 (en) 2017-01-16
CL2013002810A1 (es) 2014-02-14
KR20140014194A (ko) 2014-02-05
IL228250B (en) 2020-09-30
PT3143990T (pt) 2020-03-04
DK3143990T3 (da) 2020-03-02
US20170135967A1 (en) 2017-05-18
US9592208B2 (en) 2017-03-14
NZ615023A (en) 2016-07-29
CO6771459A2 (es) 2013-10-15
EP2694037B1 (en) 2016-10-12
EA027721B1 (ru) 2017-08-31
MY163746A (en) 2017-10-31
HUE031286T2 (hu) 2017-06-28
BR112013024430B1 (pt) 2022-02-08
AU2012236357A1 (en) 2013-10-10
WO2012135561A1 (en) 2012-10-04
CA2831600A1 (en) 2012-10-04
TW201244711A (en) 2012-11-16
HK1190309A1 (zh) 2014-07-04
EP3143990A1 (en) 2017-03-22
ECSP13012912A (es) 2013-11-29
PL2694037T3 (pl) 2017-05-31
EP3143990B1 (en) 2019-11-27
CN103476400A (zh) 2013-12-25
JP6019101B2 (ja) 2016-11-02
ES2773482T3 (es) 2020-07-13
CY1118423T1 (el) 2017-06-28
BR112013024430A2 (pt) 2016-12-20
JP2014509652A (ja) 2014-04-21
US20180193291A1 (en) 2018-07-12
SG193256A1 (en) 2013-10-30
US20200276137A1 (en) 2020-09-03
EA201790436A2 (ru) 2017-10-31
JO3177B1 (ar) 2018-03-08
MX2013011415A (es) 2013-12-09
KR102027014B1 (ko) 2019-09-30
PE20170913A1 (es) 2017-07-12
AU2012236357B2 (en) 2016-03-10
SI3143990T1 (sl) 2020-03-31
RS59917B1 (sr) 2020-03-31
CY1122868T1 (el) 2021-05-05
US20140371323A1 (en) 2014-12-18
EP2694037A1 (en) 2014-02-12
TWI528958B (zh) 2016-04-11
GT201300227A (es) 2015-05-05
PE20140162A1 (es) 2014-02-12
HRP20170021T1 (hr) 2017-03-10
ES2610966T3 (es) 2017-05-04
ZA201306636B (en) 2014-05-28
HRP20200249T1 (hr) 2020-05-15
AR085749A1 (es) 2013-10-23
CA2831600C (en) 2020-04-21

Similar Documents

Publication Publication Date Title
HRP20200249T1 (hr) Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol
BR112013008597A2 (pt) fornecimento de mercado para serviços de software
BR112014001868A2 (pt) cápsulas supramoleculares
HK1199798A1 (en) Heated insoles
EP2768921A4 (en) REFRIGERANT PREPARATIONS
BR112015003101A2 (pt) processo para a preparação de um composto.
ITMI20120020A1 (it) Set di sagomatura regolabile per scarpe
IL208019A0 (en) Process for the preparation of 2-amino-2-[2-(4-c3-c21-alkyl-phenyl) ethyl) propane-1, 3-diols
DK2686011T3 (da) Ipn-vaccine
BR112013015953A2 (pt) processo para a preparação de sais de cis-1-amônio-4-alcoxiciclohexanocarbonitrilo.
ZA201305986B (en) Improved insecticide formulations
EP2771854A4 (en) SYSTEM TO OFFER ON ADVERTISING CONTENT
ZA201306475B (en) Solid herbicidal composition comprising mesotrione
BR112013012799A2 (pt) enantiômemero ativo de dodecil 2-(n,n-dimetilamino)-propionato
GB201120001D0 (en) Herbicide applicator
SMT201600415B (it) Procedimento di preparazione di metaxalone
IT1400019B1 (it) Portacanna per pesca deambulante.
ES1074764Y (es) Protector para espatulas.
FI20110077A0 (fi) Lämpöä tuottava kenkä
GB201101410D0 (en) Heated shoe
GB201118319D0 (en) Thermal pump